BioGeometry Funding Round

10/28/2026

Venture Equity

$100,000,000

Series A

BioGeometry plans to use the funding to continue developing and improving its two AI-powered biological world models: GeoFlow, which operates at the molecular level, and GeoCell, which operates at the cellular level. The company will also expand its high-throughput automated laboratories and advance its proprietary drug-development pipeline toward commercialisation. These investments are intended to strengthen its AI-driven discovery and development capabilities across antibodies, vaccines, peptides and enzymes. The company has also indicated that several bispecific antibody programmes are expected to enter clinical trials in 2027.

Private & Independent

Biopharmaceutical

Room 604, Block A, Raycom Infotech Park, Haidian
Beijing, 100190
CN

Undisclosed

BioGeometry is a digital biology pioneer that specializes in applying generative AI to protein design. Our AI-driven biologics design platform (GeoBiologics) and high-throughput wet-lab validation platform form a design-build-test-learn closed loop, empowering precise and efficient protein design and optimization for biomedicine and synthetic biology. BioGeometry was founded in 2022 by Prof. Jian Tang, a renowned scientist in AI4Drug and deep learning on graphs, with Turing Award laureate Yoshua Bengio serving as the chief scientific advisor.